Compare XXII & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XXII | DCOY |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | 11 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.1M |
| IPO Year | 2011 | N/A |
| Metric | XXII | DCOY |
|---|---|---|
| Price | $0.56 | $5.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 1.0M | 7.5K |
| Earning Date | 05-12-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,832,530.00 | N/A |
| Revenue This Year | $370.28 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.53 |
| 52 Week High | $11.37 | $9.09 |
| Indicator | XXII | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 16.90 | 48.96 |
| Support Level | N/A | $5.28 |
| Resistance Level | $1.10 | $6.70 |
| Average True Range (ATR) | 0.21 | 0.38 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 2.44 | 50.46 |
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.